

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/107001 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/IB2021/060623

(22) International Filing Date:

16 November 2021 (16.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/115,473 18 November 2020 (18.11.2020) US
63/237,473 26 August 2021 (26.08.2021) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **JUNGE, Guido**; Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **KIFFE, Michael**; Novartis Pharma
AG, Postfach, 4002 Basel (CH). **KOVARIK, Jiri**; Novartis
Pharma AG, Postfach, 4002 Basel (CH). **STEIN, Richard**;
Novartis Pharma AG, Postfach, 4002 Basel (CH). **WAL-
DRON-LYNCH, Frank**; Novartis Institutes for BioMed-
ical Research, Inc., 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139 (US).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY

(57) Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This invention also relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of AIFEC in a subject in need thereof.

WO 2022/107001 A1